Détails des événements

Global progress against malaria has stalled in recent years. In 2024, malaria caused more than 600,000 deaths worldwide, with nearly two-thirds occurring among children under five years of age. Emerging resistance to antimalarial drugs and insecticides, declining global health funding, climate change, and humanitarian crises all threaten to reverse previous gains. At the same time, the widespread rollout of two malaria vaccines in infants across sub-Saharan Africa since 2024 marks a major milestone in malaria prevention. This PHO Rounds will describe the clinical development of the R21/Matrix-M malaria vaccine, highlighting key evidence supporting its implementation. It will also examine the evolving global malaria landscape and discuss priorities and future directions for malaria vaccine development.

Intended Audience: 
Public health physicians and nurses, public health professionals with interest in communicable disease and global health, researchers, infectious disease physicians.

By the end of this event, participants will be able to:

• Quantify and describe malaria burden, impact and threats.
• Name the tools available for malaria prevention.
• Identify current malaria licensed vaccines and be able to describe the R21/Matrix-M data.
• Discuss the future directions for malaria vaccine development and malaria elimination.

Dr. Mehreen Datoo, DPhil FRCPath MRCP MBBS BSc is a Principal Investigator at the Jenner Institute, University of Oxford, and a clinician in Infectious Diseases and Microbiology. Her PhD focused on malaria vaccine development under Professor Sir Adrian Hill, contributing to the early clinical development of the R21/Matrix-M vaccine. As Clinical Lead and Co-Investigator for Phase II and III trials, she played a key role in its development and regulatory approval, supporting WHO endorsement in 2023. She now leads research on next-generation malaria vaccines, including a programme targeting Plasmodium vivax. Her broader work spans Ebola, MERS, and COVID-19 vaccines, with a focus on equitable partnerships, capacity strengthening, and global health impact.

The opinions expressed by speakers and moderators do not necessarily reflect the official policies or views of Public Health Ontario, nor does the mention of trade names, commercial practices, or organizations imply endorsement by Public Health Ontario.

Public Health Ontario Grand Rounds are a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada (RCPSC). In order to receive written documentation for Continuing Medical Education (CME) credits, please check “Yes” beside the question “Do you require CME credits?” on the registration form.

College of Family Physicians of Canada (CFPC) Affiliate Members may count RCPSC credits toward their Mainpro+ credit requirements. All other CFPC members may claim up to 50 Certified credits per cycle for participation in RCPSC MOC Section 1 accredited activities.

PHO Grand Rounds are also approved by the Council of Professional Experience for professional development hours (PDHs) for members of the Canadian Institute of Public Health Inspectors (CIPHI).

For more information or for a record of registration for other Continuing Education purposes, please contact events@oahpp.ca

Public Health Ontario is committed to complying with the Accessibility for Ontarians with Disabilities Act (AODA). If you require accommodations to participate in this event, please contact 647-260-7100 or events@oahpp.ca.